documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
307 rows where agency_id = "DEA" and document_type = "Supporting & Related Material" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DEA-2026-0133-0004 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 HHS Letter to DEA 06112025 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T23:39:08Z | 0 | 0 | 09000064b9162339 | ||||
| DEA-2026-0133-0003 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 DEA Letter to HHS 11012024 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-02-12T21:01:03Z | 0 | 1 | 09000064b9162338 | ||||
| DEA-2026-0133-0002 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 3-Factor Analysis 2-Fluorodeschloroketamine January 2026 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T23:39:02Z | 0 | 0 | 09000064b9162337 | ||||
| DEA-2026-0133-0005 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 HHS Letter to DEA 11082024 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T23:39:10Z | 0 | 0 | 09000064b916233a | ||||
| DEA-2026-0133-0006 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 DEA Letter to HHS 05282025 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-02-12T21:01:51Z | 0 | 1 | 09000064b916233b | ||||
| DEA-2025-0918-0003 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | 251203 OASH to DEA draft letter 4 synthetic cannabinoids 8FA_signed 12032025 | Supporting & Related Material | 2025-12-18T05:00:00Z | 2025 | 12 | 2025-12-18T19:22:36Z | 0 | 0 | 09000064b90eed87 | ||||
| DEA-2025-0918-0005 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | 4F-MDMB-BUTICA ADB-4en-PINACA 5F-EDMB-PICA MMB-FUBICA 8-Factor Analysis December 2025 DEA | Supporting & Related Material | 2025-12-18T05:00:00Z | 2025 | 12 | 2025-12-18T19:22:42Z | 0 | 0 | 09000064b90eed89 | ||||
| DEA-2025-0918-0004 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | 4F-MDMB-BUTICA ADB-4en-PINACA 5F-EDMB-PICA MMB-FUBICA 8-Factor December 2025 HHS | Supporting & Related Material | 2025-12-18T05:00:00Z | 2025 | 12 | 2025-12-18T19:22:39Z | 0 | 0 | 09000064b90eed88 | ||||
| DEA-2025-0885-0003 | DEA | Schedules of Controlled Substances: Placement of Bromazolam in Schedule I (DEA1420) DEA-2025-0885 | HHS letter to DEA Bromazolam 07102025 | Supporting & Related Material | 2025-12-15T05:00:00Z | 2025 | 12 | 2025-12-15T20:47:51Z | 0 | 0 | 09000064b90d40f8 | ||||
| DEA-2025-0885-0002 | DEA | Schedules of Controlled Substances: Placement of Bromazolam in Schedule I (DEA1420) DEA-2025-0885 | HHS letter to DEA Bromazolam 06282024 | Supporting & Related Material | 2025-12-15T05:00:00Z | 2025 | 12 | 2025-12-15T20:47:46Z | 0 | 0 | 09000064b90d40f6 | ||||
| DEA-2025-0885-0004 | DEA | Schedules of Controlled Substances: Placement of Bromazolam in Schedule I (DEA1420) DEA-2025-0885 | DEA 3-Factor Analysis Bromazolam December 2025 | Supporting & Related Material | 2025-12-15T05:00:00Z | 2025 | 12 | 2025-12-15T20:47:54Z | 0 | 0 | 09000064b90d40f7 | ||||
| DEA-2025-0852-0005 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | HHS Letter to DEA cumyl-PEGACLONE_112024 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:46:04Z | 0 | 0 | 09000064b90cb028 | ||||
| DEA-2025-0852-0007 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | HHS Letter to DEA cumyl-PEGACLONE_112024 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:50:33Z | 0 | 0 | 09000064b90cb02a | ||||
| DEA-2025-0852-0006 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL-PEGACLONE HHS 8 Factor Review | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:50:28Z | 0 | 0 | 09000064b90cb029 | ||||
| DEA-2025-0852-0008 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL PEGACLONE DEA 8-Factor Analysis_1222025 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:50:36Z | 0 | 0 | 09000064b90cb02b | ||||
| DEA-2025-0852-0004 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL-PEGACLONE HHS 8 Factor Review | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:46:02Z | 0 | 0 | 09000064b90cb027 | ||||
| DEA-2025-0852-0003 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL PEGACLONE DEA 8-Factor Analysis_1222025 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:45:59Z | 0 | 0 | 09000064b90cb026 | ||||
| DEA-2025-0588-0002 | DEA | Schedules of Controlled Substances: Temporary Placement of ethyleneoxynitazene, methylenedioxynitazene, 5-methyl etodesnitazene, N-desethyl etonitazene, N-desethyl protonitazene, N,N-dimethylamino etonitazene, and N-pyrrolidino isotonitazene in Schedule I (DEA1494) DEA-2025-0588 | Seven benzimidazole opioids 811h no objection ASH to DEA 22Apr2025.AA | Supporting & Related Material | 2025-10-16T04:00:00Z | 2025 | 10 | 2025-10-17T03:33:17Z | 0 | 0 | 09000064b902eca3 | ||||
| DEA-2025-0555-0003 | DEA | Schedules of Controlled Substances: Placement of MDMB-4-PINACA in Schedule I (DEA1356) DEA-2025-0555 | 8FA MDMB-4en-PINACA | Supporting & Related Material | 2025-10-03T04:00:00Z | 2025 | 10 | 2025-10-03T22:46:34Z | 0 | 0 | 09000064b8ff1b92 | ||||
| DEA-2025-0555-0004 | DEA | Schedules of Controlled Substances: Placement of MDMB-4-PINACA in Schedule I (DEA1356) DEA-2025-0555 | SIGNED - OASH to DEA Ltr 8FA MDMB-PINACA.VAS | Supporting & Related Material | 2025-10-03T04:00:00Z | 2025 | 10 | 2025-10-03T22:46:38Z | 0 | 0 | 09000064b8ff1b94 | ||||
| DEA-2025-0555-0002 | DEA | Schedules of Controlled Substances: Placement of MDMB-4-PINACA in Schedule I (DEA1356) DEA-2025-0555 | MDMB-4en-PINACA 8F Oct 2025 | Supporting & Related Material | 2025-10-02T04:00:00Z | 2025 | 10 | 2025-10-03T01:16:43Z | 0 | 0 | 09000064b8fefe68 | ||||
| DEA-2025-0192-0002 | DEA | Specific Listing for Dipentylone, a Currently Controlled Schedule I Substance (DEA1390) DEA-2025-0192 | DEA-1494 Three Factor Analysis for Temporary Control of Seven Benzimidazole-Opioids | Supporting & Related Material | 2025-08-01T04:00:00Z | 2025 | 8 | 2025-08-02T00:46:00Z | 0 | 0 | 09000064b8ecca29 | ||||
| DEA-2022-0145-0008 | DEA | Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (DEA989) DEA-2022-0145 | DEA989 HHS 8-Factor Analysis | Supporting & Related Material | 2025-07-25T04:00:00Z | 2025 | 7 | 2025-07-25T21:33:08Z | 0 | 0 | 09000064b8ea2f07 | ||||
| DEA-2022-0145-0007 | DEA | Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (DEA989) DEA-2022-0145 | DEA989 DEA 8-Factor Analysis | Supporting & Related Material | 2025-07-25T04:00:00Z | 2025 | 7 | 2025-07-25T21:33:05Z | 0 | 0 | 09000064b8e9d6f4 | ||||
| DEA-2025-0078-0003 | DEA | Three specific fentanyl-related substances (para-bromofentanyl, para-fluoroacetyl fentanyl, and para-methyl acetyl fentanyl) (DEA1484) DEA-2025-0078 | DEA Eight Factor 3 FRS_2025 | Supporting & Related Material | 2025-06-13T04:00:00Z | 2025 | 6 | 2025-06-13T19:26:14Z | 0 | 0 | 09000064b8e081ed | ||||
| DEA-2025-0078-0002 | DEA | Three specific fentanyl-related substances (para-bromofentanyl, para-fluoroacetyl fentanyl, and para-methyl acetyl fentanyl) (DEA1484) DEA-2025-0078 | 3 FRS 8FA Review | Supporting & Related Material | 2025-06-13T04:00:00Z | 2025 | 6 | 2025-06-13T19:25:56Z | 0 | 0 | 09000064b8e081ec | ||||
| DEA-2025-0081-0004 | DEA | Placement of 3-methoxyphencyclidine (1-[1-(3-methoxyphenyl)cyclohexyl] piperidine) in Schedule I (DEA1146) DEA-2025-0081 | SIGNED - OASH to DEA Ltr 3-MeO PCP.VAS | Supporting & Related Material | 2025-06-10T04:00:00Z | 2025 | 6 | 2025-06-10T17:28:14Z | 0 | 0 | 09000064b8ddfd9d | ||||
| DEA-2025-0081-0002 | DEA | Placement of 3-methoxyphencyclidine (1-[1-(3-methoxyphenyl)cyclohexyl] piperidine) in Schedule I (DEA1146) DEA-2025-0081 | DEA1146 8 Factor 3-MeO-PCP | Supporting & Related Material | 2025-06-10T04:00:00Z | 2025 | 6 | 2025-06-10T17:27:40Z | 0 | 0 | 09000064b8ddfd9b | ||||
| DEA-2025-0081-0003 | DEA | Placement of 3-methoxyphencyclidine (1-[1-(3-methoxyphenyl)cyclohexyl] piperidine) in Schedule I (DEA1146) DEA-2025-0081 | HHS 8FA 3-MeO-PCP Review | Supporting & Related Material | 2025-06-10T04:00:00Z | 2025 | 6 | 2025-06-10T17:27:57Z | 0 | 0 | 09000064b8ddfd9c | ||||
| DEA-2025-0075-0002 | DEA | Placement of 4-Fluoroamphetamine in Schedule I (DEA1180) DEA-2025-0075 | 8FA HHS Report Review 4-Fluoroamphetamine | Supporting & Related Material | 2025-06-03T04:00:00Z | 2025 | 6 | 2025-06-03T21:10:52Z | 0 | 0 | 09000064b8dd15a3 | ||||
| DEA-2025-0075-0003 | DEA | Placement of 4-Fluoroamphetamine in Schedule I (DEA1180) DEA-2025-0075 | FINAL SIGNED - OASH Letter to DEA Ltr 4-Fluroamphetamine | Supporting & Related Material | 2025-06-03T04:00:00Z | 2025 | 6 | 2025-06-03T21:11:11Z | 0 | 0 | 09000064b8dd15a4 | ||||
| DEA-2025-0075-0004 | DEA | Placement of 4-Fluoroamphetamine in Schedule I (DEA1180) DEA-2025-0075 | DEA1180 Background Review 4-Fluoroamphetamine | Supporting & Related Material | 2025-06-03T04:00:00Z | 2025 | 6 | 2025-06-03T21:11:41Z | 0 | 0 | 09000064b8dd15a5 | ||||
| DEA-2024-0148-0004 | DEA | Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act (DEA1457) DEA-2024-0148 | 7-FRS HHS 8FA Review | Supporting & Related Material | 2024-12-31T05:00:00Z | 2024 | 12 | 2024-12-31T17:10:13Z | 0 | 0 | 09000064868970a9 | ||||
| DEA-2024-0148-0003 | DEA | Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act (DEA1457) DEA-2024-0148 | SIGNED OASH to DEA letter 7FRS 8FA_10.25.24 | Supporting & Related Material | 2024-12-31T05:00:00Z | 2024 | 12 | 2024-12-31T17:09:46Z | 0 | 0 | 09000064868970aa | ||||
| DEA-2024-0148-0005 | DEA | Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I of the Controlled Substances Act (DEA1457) DEA-2024-0148 | 7-FRS DEA 8 Factor Analysis_2024 | Supporting & Related Material | 2024-12-31T05:00:00Z | 2024 | 12 | 2024-12-31T17:10:26Z | 0 | 0 | 09000064868970a8 | ||||
| DEA-2024-0144-0003 | DEA | Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I (DEA1246) DEA-2024-0144 | 4-CMC HHS 8FA Review | Supporting & Related Material | 2024-12-30T05:00:00Z | 2024 | 12 | 2024-12-30T17:15:04Z | 0 | 0 | 0900006486891597 | ||||
| DEA-2024-0144-0004 | DEA | Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I (DEA1246) DEA-2024-0144 | 4-CMC DEA 8 Factor Analysis_092024 | Supporting & Related Material | 2024-12-30T05:00:00Z | 2024 | 12 | 2024-12-30T17:15:09Z | 0 | 0 | 0900006486891598 | ||||
| DEA-2024-0144-0002 | DEA | Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I (DEA1246) DEA-2024-0144 | SIGNED - OASH to DEA Ltr 4-CMC.VAS | Supporting & Related Material | 2024-12-30T05:00:00Z | 2024 | 12 | 2024-12-30T17:15:00Z | 0 | 0 | 0900006486891596 | ||||
| DEA-2024-0118-0002 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (DEA1337) DEA-2024-0118 | DEA-1337 Three Factor Analysis for Temporary Control of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene | Supporting & Related Material | 2024-09-17T04:00:00Z | 2024 | 9 | 2024-09-17T20:07:23Z | 0 | 0 | 0900006486732f62 | ||||
| DEA-2024-0059-0007 | DEA | Schedules of Controlled Substances: Rescheduling of Marijuana DEA-2024-0059 | 2016-17954-DEA-426 | Supporting & Related Material | 2024-05-21T04:00:00Z | 2024 | 5 | 2024-05-21T13:55:44Z | 0 | 0 | 090000648657624c | ||||
| DEA-2024-0059-0006 | DEA | Schedules of Controlled Substances: Rescheduling of Marijuana DEA-2024-0059 | 2016-17954-HHS | Supporting & Related Material | 2024-05-21T04:00:00Z | 2024 | 5 | 2024-05-21T13:55:31Z | 0 | 0 | 090000648657624b | ||||
| DEA-2024-0059-0004 | DEA | Schedules of Controlled Substances: Rescheduling of Marijuana DEA-2024-0059 | 2024-04-11 - AAG Fonzone - Marijuana Rescheduling | Supporting & Related Material | 2024-05-21T04:00:00Z | 2024 | 5 | 2024-05-21T13:46:37Z | 0 | 0 | 0900006486576249 | ||||
| DEA-2024-0059-0005 | DEA | Schedules of Controlled Substances: Rescheduling of Marijuana DEA-2024-0059 | 2016-17960-DEA-427 | Supporting & Related Material | 2024-05-21T04:00:00Z | 2024 | 5 | 2024-05-21T13:55:07Z | 0 | 0 | 090000648657624a | ||||
| DEA-2023-0168-0004 | DEA | Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (DEA1156) DEA-2023-0168 | FINAL SIGNED ASH Letter to DEA_DOI-DOC_09.28.2020 | Supporting & Related Material | 2023-12-14T05:00:00Z | 2023 | 12 | 2023-12-14T16:35:38Z | 0 | 0 | 090000648633a0c2 | ||||
| DEA-2023-0168-0005 | DEA | Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (DEA1156) DEA-2023-0168 | DEA1156 Eight-Factor Review DOI DOC 102023 | Supporting & Related Material | 2023-12-14T05:00:00Z | 2023 | 12 | 2023-12-14T16:35:46Z | 0 | 0 | 090000648633a0c3 | ||||
| DEA-2023-0049-0006 | DEA | Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (DEA1006) DEA-2023-0049 | SIGNED - 6 Cannabinoids 811h no objection ASH to DEA.VAS (003) MDC 03072022 | Supporting & Related Material | 2023-12-12T05:00:00Z | 2023 | 12 | 2023-12-12T15:13:43Z | 0 | 0 | 0900006486329b0d | ||||
| DEA-2023-0049-0005 | DEA | Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (DEA1006) DEA-2023-0049 | 6 SCs 3 Factor December 2023 | Supporting & Related Material | 2023-12-12T05:00:00Z | 2023 | 12 | 2023-12-12T15:13:34Z | 0 | 0 | 09000064863298d2 | ||||
| DEA-2023-0147-0002 | DEA | Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (DEA1143) DEA-2023-0147 | DEA 1143 Three Factor Analysis for Temporary Control of N-desethyl isotonitazene and N-piperidinyl etonitazene | Supporting & Related Material | 2023-11-06T05:00:00Z | 2023 | 11 | 2023-11-06T19:47:05Z | 0 | 0 | 090000648621047f | ||||
| DEA-2023-0149-0002 | DEA | Placement of Zuranolone in Schedule IV (DEA1258) DEA-2023-0149 | DEA1258 Zuranolone Eight Factors of Analysis September 2023 | Supporting & Related Material | 2023-10-31T04:00:00Z | 2023 | 10 | 2023-10-31T17:39:29Z | 0 | 0 | 09000064861a5b33 | ||||
| DEA-2023-0149-0003 | DEA | Placement of Zuranolone in Schedule IV (DEA1258) DEA-2023-0149 | ASH to DEA Letter and 8FA Zuranolone 12Jul2023 | Supporting & Related Material | 2023-10-31T04:00:00Z | 2023 | 10 | 2023-10-31T17:39:40Z | 0 | 0 | 09000064861a5b32 | ||||
| DEA-2023-0129-0002 | DEA | Placement of Ethylphenidate in Schedule I (DEA1142) DEA-2023-0129 | Ethylphenidate 8-Factor DOE 23-103 | Supporting & Related Material | 2023-09-22T04:00:00Z | 2023 | 9 | 2023-09-22T19:17:09Z | 0 | 0 | 0900006485fe8668 | ||||
| DEA-2023-0049-0003 | DEA | Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (DEA1006) DEA-2023-0049 | SIGNED - 6 Cannabinoids 811h no objection ASH to DEA.VAS (003) MDC 03072022 | Supporting & Related Material | 2023-05-11T04:00:00Z | 2023 | 5 | 2023-05-11T12:54:36Z | 0 | 0 | 09000064859f43b8 | ||||
| DEA-2023-0058-0002 | DEA | Placement of Nine Specific Fentanyl Related Substances in Schedule I (DEA1036) DEA-2023-0058 | FINAL SIGNED - ASHtoDEA draft letter 9 Fentanyl-Related Substances.VAS | Supporting & Related Material | 2023-04-14T04:00:00Z | 2023 | 4 | 2023-04-14T12:21:41Z | 0 | 0 | 09000064859444a7 | ||||
| DEA-2023-0058-0003 | DEA | Placement of Nine Specific Fentanyl Related Substances in Schedule I (DEA1036) DEA-2023-0058 | DEA1036 Nine fentanyls 8-factor 04.06.2023 | Supporting & Related Material | 2023-04-14T04:00:00Z | 2023 | 4 | 2023-04-14T12:21:56Z | 0 | 0 | 09000064859444a8 | ||||
| DEA-2023-0058-0004 | DEA | Placement of Nine Specific Fentanyl Related Substances in Schedule I (DEA1036) DEA-2023-0058 | 8FA Nine Fentanyls | Supporting & Related Material | 2023-04-14T04:00:00Z | 2023 | 4 | 2023-04-14T12:22:09Z | 0 | 0 | 09000064859444a9 | ||||
| DEA-2023-0049-0002 | DEA | Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (DEA1006) DEA-2023-0049 | 6 SCs 3 Factor April 2022 | Supporting & Related Material | 2023-04-04T04:00:00Z | 2023 | 4 | 2023-04-04T15:48:44Z | 0 | 0 | 09000064858c4960 | ||||
| DEA-2022-0068-0005 | DEA | Schedules of Controlled Substances: Removal of Fenfluramine From Control DEA-2022-0068 | FINAL SIGNED - Fenfluramine Letter and 8FA review 16Apr2021 | Supporting & Related Material | 2023-01-03T05:00:00Z | 2023 | 1 | 2023-01-03T13:21:30Z | 0 | 0 | 090000648557e6b8 | ||||
| DEA-2022-0068-0004 | DEA | Schedules of Controlled Substances: Removal of Fenfluramine From Control DEA-2022-0068 | DEA945 Eight Factor Analysis Fenfluramine 012022 | Supporting & Related Material | 2023-01-03T05:00:00Z | 2023 | 1 | 2023-01-03T13:21:26Z | 0 | 0 | 090000648556a0f0 | ||||
| DEA-2022-0145-0002 | DEA | Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (DEA989) DEA-2022-0145 | DEA 3-Factor Analysis Etizolam Flualprazolam Clonazolam Diclazepam Flu... | Supporting & Related Material | 2022-12-23T05:00:00Z | 2022 | 12 | 2022-12-23T12:56:32Z | 0 | 0 | 090000648554cfbd | ||||
| DEA-2022-0145-0003 | DEA | Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (DEA989) DEA-2022-0145 | SIGNED - Benzodiazepines 811h no objection ASH to DEA.VAS | Supporting & Related Material | 2022-12-23T05:00:00Z | 2022 | 12 | 2022-12-23T12:56:40Z | 0 | 0 | 090000648554cfbe | ||||
| DEA-2022-0051-0004 | DEA | Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V DEA-2022-0051 | Ganaxolone eight factor_DEA | Supporting & Related Material | 2022-11-09T05:00:00Z | 2022 | 11 | 2022-11-09T16:41:53Z | 0 | 0 | 090000648549e073 | ||||
| DEA-2022-0051-0003 | DEA | Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V DEA-2022-0051 | Ganaxolone 8FA | Supporting & Related Material | 2022-11-09T05:00:00Z | 2022 | 11 | 2022-11-09T16:41:43Z | 0 | 0 | 090000648549e072 | ||||
| DEA-2022-0108-0002 | DEA | Importer of Controlled Substances Application: Chattem Chemicals, Inc. (DEA1083) DEA-2022-0108 | Bulk Manufacturer Application - Chattem Chemicals - Correction (2022-24105) - DEA1083 | Supporting & Related Material | 2022-11-08T05:00:00Z | 2022 | 11 | 2022-11-08T13:25:42Z | 0 | 0 | 0900006485499735 | ||||
| DEA-2022-0026-0003 | DEA | Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I DEA-2022-0026 | DEA824 DEA 8-factor_DOIandDOC_DOE_082021 | Supporting & Related Material | 2022-04-11T04:00:00Z | 2022 | 4 | 2022-04-11T14:27:34Z | 0 | 0 | 090000648500b68f | ||||
| DEA-2022-0026-0002 | DEA | Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I DEA-2022-0026 | FINAL SIGNED ASH Letter to DEA_DOI-DOC_09.28.2020 | Supporting & Related Material | 2022-04-11T04:00:00Z | 2022 | 4 | 2022-04-11T14:27:28Z | 0 | 0 | 090000648500b69e | ||||
| DEA-2022-0025-0003 | DEA | Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV DEA-2022-0025 | Daridorexant eight factor document DOE | Supporting & Related Material | 2022-04-07T04:00:00Z | 2022 | 4 | 2022-04-07T13:15:47Z | 0 | 0 | 0900006484fff9ea | ||||
| DEA-2022-0025-0002 | DEA | Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV DEA-2022-0025 | Daridorexant ASHtoDEA 22Dec2021 | Supporting & Related Material | 2022-04-07T04:00:00Z | 2022 | 4 | 2022-04-07T13:15:39Z | 0 | 0 | 0900006484fff9e9 | ||||
| DEA-2022-0025-0004 | DEA | Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV DEA-2022-0025 | DCT to DEA daridorexant NDA approval notification | Supporting & Related Material | 2022-04-07T04:00:00Z | 2022 | 4 | 2022-04-07T13:15:53Z | 0 | 0 | 0900006484fff7f5 | ||||
| DEA-2022-0001-0002 | DEA | Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I DEA-2022-0001 | 4-OH-DIPT Schedule I_05-17-2012 | Supporting & Related Material | 2022-01-14T05:00:00Z | 2022 | 1 | 2022-01-14T18:38:33Z | 0 | 0 | 0900006484f21925 | ||||
| DEA-2022-0001-0004 | DEA | Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I DEA-2022-0001 | 5-MeO-DET Schedule I_05-17-2012 | Supporting & Related Material | 2022-01-14T05:00:00Z | 2022 | 1 | 2022-01-14T18:38:55Z | 0 | 0 | 0900006484f21930 | ||||
| DEA-2022-0001-0006 | DEA | Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I DEA-2022-0001 | DIPT Schedule I_08-14-2012 | Supporting & Related Material | 2022-01-14T05:00:00Z | 2022 | 1 | 2022-01-14T18:39:32Z | 0 | 0 | 0900006484f21933 | ||||
| DEA-2022-0001-0003 | DEA | Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I DEA-2022-0001 | 5-MeO-AMT Schedule I_04-03-2012 | Supporting & Related Material | 2022-01-14T05:00:00Z | 2022 | 1 | 2022-01-14T18:38:44Z | 0 | 0 | 0900006484f21926 | ||||
| DEA-2022-0001-0005 | DEA | Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I DEA-2022-0001 | Five tryptamines Eight-factor analysis DEA 082021 | Supporting & Related Material | 2022-01-14T05:00:00Z | 2022 | 1 | 2022-01-14T18:39:21Z | 0 | 0 | 0900006484f21932 | ||||
| DEA-2022-0001-0007 | DEA | Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I DEA-2022-0001 | 5-MeO-MIPT Schedule I_05-17-2012 | Supporting & Related Material | 2022-01-14T05:00:00Z | 2022 | 1 | 2022-01-14T18:39:43Z | 0 | 0 | 0900006484f21934 | ||||
| DEA-2021-0031-0003 | DEA | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I DEA-2021-0031 | Three Factor Analysis for Temporary Control of 7 benzimidazole-opioids | Supporting & Related Material | 2021-12-13T05:00:00Z | 2021 | 12 | 2021-12-13T15:48:07Z | 0 | 0 | 0900006484ec1629 | ||||
| DEA-2021-0030-0003 | DEA | Schedules of Controlled Substances: Placement of Methoxetamine in Schedule I DEA-2021-0030 | DEA568 8 Factor Methoxetamine 092021 | Supporting & Related Material | 2021-12-08T05:00:00Z | 2021 | 12 | 2021-12-08T20:11:47Z | 0 | 0 | 0900006484eac53f | ||||
| DEA-2021-0030-0002 | DEA | Schedules of Controlled Substances: Placement of Methoxetamine in Schedule I DEA-2021-0030 | HHS Scheduling recommendation Methoxetamine | Supporting & Related Material | 2021-12-08T05:00:00Z | 2021 | 12 | 2021-12-08T20:11:38Z | 0 | 0 | 0900006484eac53d | ||||
| DEA-2021-0031-0002 | DEA | Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-pyrrolidino etonitazene, and Protonitazene in Schedule I DEA-2021-0031 | Three Factor Analysis for Temporary Control of 7 benzimidazole-opioids 11042021 | Supporting & Related Material | 2021-12-08T00:00:00Z | 2021 | 12 | 2021-12-13T15:47:53Z | 0 | 1 | 0900006484eac53c | ||||
| DEA-2021-0025-0003 | DEA | Schedules of Controlled Substances: Removal of [18F]FP-CIT from Control DEA-2021-0025 | DEA837 8FA 18F FP-CIT DOE-21-632 | Supporting & Related Material | 2021-11-04T04:00:00Z | 2021 | 11 | 2021-11-04T13:48:03Z | 0 | 0 | 0900006484e1a226 | ||||
| DEA-2021-0025-0002 | DEA | Schedules of Controlled Substances: Removal of [18F]FP-CIT from Control DEA-2021-0025 | FINAL SIGNED - Fluoroseek Letter and review 16Apr2021 | Supporting & Related Material | 2021-11-04T04:00:00Z | 2021 | 11 | 2021-11-04T13:47:50Z | 0 | 0 | 0900006484e1a93b | ||||
| DEA-2021-0012-0002 | DEA | Schedules of Controlled Substances: Placement of Mesocarb in Schedule I DEA-2021-0012 | Mesocarb 8 Factor August 2021 | Supporting & Related Material | 2021-08-17T04:00:00Z | 2021 | 8 | 2021-08-17T15:02:59Z | 0 | 0 | 0900006484c6c92b | ||||
| DEA-2021-0012-0003 | DEA | Schedules of Controlled Substances: Placement of Mesocarb in Schedule I DEA-2021-0012 | HHS recommendation on Mesocarb Apr 3 2012 | Supporting & Related Material | 2021-08-17T04:00:00Z | 2021 | 8 | 2021-08-17T15:05:58Z | 0 | 0 | 0900006484c6c92d | ||||
| DEA-2021-0011-0002 | DEA | Schedules of Controlled Substances: Placement of Amineptine in Schedule I DEA-2021-0011 | Aminpetine 8-factor July 2021 | Supporting & Related Material | 2021-07-27T04:00:00Z | 2021 | 7 | 2021-07-27T13:52:16Z | 0 | 0 | 0900006484c127b0 | ||||
| DEA-2021-0011-0003 | DEA | Schedules of Controlled Substances: Placement of Amineptine in Schedule I DEA-2021-0011 | Amineptine (DHHS) 12-01-2011 | Supporting & Related Material | 2021-07-27T04:00:00Z | 2021 | 7 | 2021-07-27T13:52:23Z | 0 | 0 | 0900006484c127b1 | ||||
| DEA-2019-0004-0004 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8, and 4-Chloro-a-PVP in Schedule I DEA-2019-0004 | DEA_495_8 Factor_Analysis | Supporting & Related Material | 2021-07-16T04:00:00Z | 2021 | 7 | 2021-08-18T13:26:26Z | 0 | 0 | 0900006484bfe470 | ||||
| DEA-2019-0004-0005 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8, and 4-Chloro-a-PVP in Schedule I DEA-2019-0004 | OASH to DEA Letter and 8FA 6 Cathinones SIGNED 7.8.2021 | Supporting & Related Material | 2021-07-16T04:00:00Z | 2021 | 7 | 2021-08-18T13:26:40Z | 0 | 0 | 0900006484bfe471 | ||||
| DEA-2020-0003-0012 | DEA | Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V DEA-2020-0003 | Lasmiditan HHS ltr and 8 Factor Analysis 10-23-2019 | Supporting & Related Material | 2021-05-25T04:00:00Z | 2021 | 5 | 2021-05-25T16:24:36Z | 0 | 0 | 0900006484b34b97 | ||||
| DEA-2020-0003-0011 | DEA | Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V DEA-2020-0003 | 8F Lasmiditan 08062020 | Supporting & Related Material | 2021-05-25T04:00:00Z | 2021 | 5 | 2021-05-25T16:16:24Z | 0 | 0 | 0900006484b34b5d | ||||
| DEA-2021-0010-0002 | DEA | Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV DEA-2021-0010 | Serdexmethylphenidate 8-Factor Analysis DEA 04-2021 | Supporting & Related Material | 2021-05-19T04:00:00Z | 2021 | 5 | 2021-05-19T13:04:09Z | 0 | 0 | 0900006484b1ad0b | ||||
| DEA-2021-0010-0003 | DEA | Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV DEA-2021-0010 | 8FA Serdexmethylphenidate 01Mar2021 | Supporting & Related Material | 2021-05-19T04:00:00Z | 2021 | 5 | 2021-05-19T13:04:25Z | 0 | 0 | 0900006484b1ad0c | ||||
| DEA-2019-0002-0006 | DEA | Schedules of Controlled Substances: Placement of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I DEA-2019-0002 | HHS Letter 09062018 5F-EDMB-PINACA 5F-MDMB-PICA FUB-AKB48 5F-CUMYL-PINACA FUB-144 | Supporting & Related Material | 2021-04-02T04:00:00Z | 2021 | 4 | 2021-04-02T12:38:48Z | 0 | 0 | 0900006484a93780 | ||||
| DEA-2019-0002-0007 | DEA | Schedules of Controlled Substances: Placement of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I DEA-2019-0002 | 5 SC 8-Factor for permanent control March 2021 | Supporting & Related Material | 2021-04-02T04:00:00Z | 2021 | 4 | 2021-04-02T12:40:02Z | 0 | 0 | 0900006484a9376a | ||||
| DEA-2019-0002-0008 | DEA | Schedules of Controlled Substances: Placement of 5F-EDMBPINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I DEA-2019-0002 | Final Signed OASH to DEA Letter Five Synthetic Cannabinoids 2.26.21 | Supporting & Related Material | 2021-04-02T04:00:00Z | 2021 | 4 | 2021-04-02T12:43:55Z | 0 | 0 | 0900006484a93786 | ||||
| DEA-2021-0007-0002 | DEA | Schedules of Controlled Substances: Placement of Four Specific Fentanyl-Related Substances in Schedule I DEA-2021-0007 | FINAL SIGNED - OASH Letter to DEA Four FRS.VAS | Supporting & Related Material | 2021-03-22T04:00:00Z | 2021 | 3 | 2021-03-22T14:52:30Z | 0 | 0 | 0900006484a73bef | ||||
| DEA-2021-0007-0003 | DEA | Schedules of Controlled Substances: Placement of Four Specific Fentanyl-Related Substances in Schedule I DEA-2021-0007 | Four fentanyl related substances DEA 8-Factor | Supporting & Related Material | 2021-03-22T04:00:00Z | 2021 | 3 | 2021-03-22T14:57:00Z | 0 | 0 | 0900006484a73c3e | ||||
| DEA-2021-0006-0003 | DEA | Schedules of Controlled Substances: Placement of 10 Specific Fentanyl-Related Substances into Schedule I DEA-2021-0006 | Signed OASH Letter to DEA with Review 02Jul20 | Supporting & Related Material | 2021-03-09T05:00:00Z | 2021 | 3 | 2021-03-09T14:01:14Z | 0 | 0 | 0900006484a64123 | ||||
| DEA-2021-0006-0002 | DEA | Schedules of Controlled Substances: Placement of 10 Specific Fentanyl-Related Substances into Schedule I DEA-2021-0006 | DEA Eight-Factor Analysis for 10 FRS | Supporting & Related Material | 2021-03-09T05:00:00Z | 2021 | 3 | 2021-03-09T14:01:02Z | 0 | 0 | 0900006484a64120 | ||||
| DEA-2020-0020-0003 | DEA | Schedules of Controlled Substances: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I DEA-2020-0020 | 5 SCs 8-Factor for permanent control 06302020 | Supporting & Related Material | 2021-02-02T05:00:00Z | 2021 | 2 | 2021-02-02T15:27:15Z | 0 | 0 | 0900006484a1430f | ||||
| DEA-2020-0020-0005 | DEA | Schedules of Controlled Substances: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I DEA-2020-0020 | Five Syn Cannabinoids 8FA Report | Supporting & Related Material | 2021-02-02T05:00:00Z | 2021 | 2 | 2021-02-02T15:27:43Z | 0 | 0 | 0900006484a14311 | ||||
| DEA-2020-0020-0004 | DEA | Schedules of Controlled Substances: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I DEA-2020-0020 | FINAL SIGNED Response Letter to Uttam Dhillon_5.29.2020 | Supporting & Related Material | 2021-02-02T05:00:00Z | 2021 | 2 | 2021-02-02T15:27:32Z | 0 | 0 | 0900006484a14310 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;